drug

mifepristone

1 story · latest Jul 29, 2026

Status: FDA approved Sep 2000 · NDA020687, NDA202107
Brands: Korlym, Mifeprex

Relationships

Developed by Corcept Therapeutics

Timeline

Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarter

Jul 29Quarterly updateCorcept Therapeutics mifepristone

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.